Abstract
Warfarin is widely used in atrial fibrillation (AF) with concomitant end-stage renal disease (ESRD) for stroke prophylaxis but has been associated with a ten-fold higher bleeding risk due to labile INR levels. Rivaroxaban emerged as a potential alternative in these patients but its safety and
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
